ME/CFS Science @mecfsscience.org · 03/04/202610) The POST-EXERTIONAL MALAISE group looked at the percentage with no symptoms of moderate or greater severity with 50% or more frequency on the DSQ-PEM short form. This was 25.5% in the Paxlovid group and 33.3% in the placebo group (p: 0.186). 180
ME/CFS Science @mecfsscience.org · 03/04/202611) The objective measure in the POST-EXERTIONAL MALAISE group was the percentage with an improvement of at least 3 minutes on the endurance shuttle walk test. Here, the Paxlovid actually did significantly worse: 16.7% versus 30.6% (p-value: 0.014). 190
ME/CFS Science @mecfsscience.org · 03/04/202612) Otherwise, the number of adverse events seems low and similar in the groups, so I don't think this was a major issue in the trial. There was no mortality, and around 4-5% in each group had ‘Serious Adverse Events’. 160
